Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status Meeting Abstract

  

Authors:	Alessi, J. V. M.; Ricciuti, B.; Aguilar, E. J.; Hong, F.; Wei, Z.; Nishino, M.; Plodkowski, A. J.; Sawan, P.; Luo, J.; Rizvi, H.; Carter, B. W.; Heymach, J.; Altan, M.; Hellmann, M. D.; Awad, M. M.
Abstract Title:	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Start Page:	485s
Language:	English
ACCESSION:	WOS:000560368303467
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.9568
Notes:	Meeting Abstract: 9568 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/172813